TMS Co., Ltd. (JP:4891) has released an update.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
TMS Co., Ltd., a clinical-stage biopharmaceutical company, is making strides with its promising lead program, TMS-007, aimed at treating acute ischemic stroke, a field that hasn’t seen a new drug in decades. The company’s CEO, Takuro Wakabayashi, highlighted this potential breakthrough and discussed an emerging pipeline addressing hypertension, kidney injury, and spinal cord injury during an interview on Biotech TV.
For further insights into JP:4891 stock, check out TipRanks’ Stock Analysis page.